Compare NYAX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | ARDX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.6B |
| IPO Year | 2022 | 2014 |
| Metric | NYAX | ARDX |
|---|---|---|
| Price | $57.83 | $5.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $49.50 | $15.14 |
| AVG Volume (30 Days) | 11.1K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $25.96 | $38.22 |
| Revenue Next Year | $19.69 | $33.85 |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.38 | $3.50 |
| 52 Week High | $60.77 | $8.40 |
| Indicator | NYAX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 36.90 |
| Support Level | $42.63 | $5.49 |
| Resistance Level | $60.77 | $6.23 |
| Average True Range (ATR) | 1.38 | 0.31 |
| MACD | 0.55 | -0.06 |
| Stochastic Oscillator | 97.03 | 13.56 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.